Rhythm Pharmaceuticals, Inc.
NASDAQ: RYTM0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David Meeker
- Employees
- 283
- Headquarters
- Boston, United States
- IPO year
- 2017
- Market cap
- $6.6B
- Website
- https://www.rhythmtx.com
Loading RYTM…
Loading profile data…Frequently asked questions about RYTM
What does Rhythm Pharmaceuticals, Inc. (RYTM) do?
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indica...
Where does RYTM trade?
Rhythm Pharmaceuticals, Inc. (RYTM) trades on the NASDAQ Global Market.
What sector is RYTM in?
Rhythm Pharmaceuticals, Inc. (RYTM) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Rhythm Pharmaceuticals, Inc.?
David Meeker is the chief executive officer of Rhythm Pharmaceuticals, Inc. (RYTM).
Where is Rhythm Pharmaceuticals, Inc. headquartered?
Rhythm Pharmaceuticals, Inc. is headquartered in United States.
Does RYTM pay a dividend?
Rhythm Pharmaceuticals, Inc. (RYTM) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RYTM go public?
Rhythm Pharmaceuticals, Inc. (RYTM) completed its initial public offering in 2017.